These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22528586)

  • 21. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
    Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
    Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
    Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
    Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
    Lin VC; Liao CH; Kuo HC
    Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
    World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Male patients with a higher frequency of nocturnal urinary episodes are more likely to benefit from alpha-blocker therapy for bothersome nocturia.
    Lee CL; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O174-O179. PubMed ID: 30548822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS.
    Salah Azab S; Elsheikh MG
    Aging Male; 2015 Jun; 18(2):89-92. PubMed ID: 25295872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.
    Matsuo T; Miyata Y; Kakoki K; Yuzuriha M; Asai A; Ohba K; Sakai H
    BMC Urol; 2016 Jul; 16(1):45. PubMed ID: 27473059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
    Verheggen BG; Lee R; Lieuw On MM; Treur MJ; Botteman MF; Kaplan SA; Trocio JN
    J Med Econ; 2012; 15(3):586-600. PubMed ID: 22332704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
    BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
    Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
    Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data.
    Cho MC; Yoo S; Park J; Cho SY; Son H; Oh SJ; Paick JS
    BJU Int; 2019 May; 123(5A):E34-E42. PubMed ID: 30582661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H; Zong H; Cui Y; Li N; Zhang Y
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
    Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
    Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms.
    Kaplan SA; Reis RB; Cologna A; Suaid HJ; Martins AC; Kohn IJ; Te AE
    Urology; 1998 Jul; 52(1):12-6. PubMed ID: 9671862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms.
    Park YH; Kim TH; Lee SW; Chung BH; Cho JS; Lee JY
    Low Urin Tract Symptoms; 2017 May; 9(2):75-81. PubMed ID: 28394492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [EFFECT OF TADALAFIL THAT WAS ADDITIONALLY ADMINISTERED TO PATIENTS RECEIVING AN ALPHA1-BLOCKER IN JAPANESE MEN WITH LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BENIGN PROSTATIC HYPERPLASIA].
    Hayashi K; Fukagai T; Koshikiya A; Igarashi A; Morita M; Sasaki H; Ishikawa K
    Nihon Hinyokika Gakkai Zasshi; 2016; 107(1):28-33. PubMed ID: 28132988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
    Lojanapiwat B; Permpongkosol S
    Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.